Group 1 - A class action has been filed against Sage Therapeutics, Inc. on behalf of investors who purchased securities between April 12, 2021, and July 23, 2024 [1][2] - The allegations include that Sage Therapeutics misled investors regarding the efficacy of its drugs, specifically zuranolone, SAGE-718, and SAGE-324, which were claimed to be less effective than represented [2] - The complaint states that the company's public statements were materially false and misleading, affecting the perceived clinical, regulatory, and commercial prospects of its products [2] Group 2 - Shareholders interested in serving as lead plaintiff must submit their application by October 28, 2024, and can choose to remain absent class members without participating in the case [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless the case is won [4] - Robbins LLP has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5]

Core Viewpoint - The article discusses a class action lawsuit against Sage Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the effectiveness of its drug candidates and subsequent stock price declines [1][4][5]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Korver v. Sage Therapeutics, Inc., and covers purchasers of Sage Therapeutics securities from April 12, 2021, to July 23, 2024 [1]. - Investors have until October 28, 2024, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Sage Therapeutics and its executives made false statements about the effectiveness of zuranolone, dalzanemdor, and SAGE-324, leading to inflated stock prices [4][5][6]. Group 2: Drug Candidates and Allegations - Sage Therapeutics is developing zuranolone for postpartum depression (PPD) and major depressive disorder (MDD), in collaboration with Biogen [3]. - The lawsuit claims that zuranolone was less effective for MDD than represented, and the FDA was unlikely to approve its NDA for MDD in its current form [4]. - Dalzanemdor was alleged to be less effective for mild cognitive impairment (MCI) due to Parkinson's Disease (PD) than claimed, and its clinical prospects were overstated [4][6]. - SAGE-324 was also claimed to be less effective for essential tremor (ET) than suggested, with its clinical prospects similarly overstated [4][7]. Group 3: Stock Price Impact - Following the disclosure on August 4, 2023, regarding the FDA's limited approval of zuranolone, Sage Therapeutics' stock price fell nearly 54% [5]. - After the April 17, 2024, announcement that dalzanemdor did not meet its primary endpoint, the stock price dropped nearly 20% [6]. - On July 24, 2024, the announcement regarding SAGE-324's failure to demonstrate significant efficacy led to a nearly 21% decline in stock price [7][8].

NEW YORK, Aug. 31, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024. So What: If you purchased Sage securities during the Class Period ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"). Investors h ...

Core Viewpoint - A class action lawsuit has been filed against Sage Therapeutics, Inc. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its drug efficacy and regulatory prospects [1][2][3]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive [2]. Case Details - The Complaint alleges that throughout the Class Period, the defendants made false statements regarding: - The effectiveness of zuranolone in treating Major Depressive Disorder (MDD), suggesting it was less effective than claimed [3] - The likelihood of FDA approval for the Zuranolone New Drug Application (NDA) for MDD, which was deemed unlikely in its current form [3] - The effectiveness of SAGE-718 in treating Mild Cognitive Impairment (MCI) due to Parkinson's Disease (PD), which was overstated [3] - The effectiveness of SAGE-324 in treating Essential Tremor (ET), which was also overstated [3] - As a result, the company's public statements were materially false and misleading at all relevant times [3]. Next Steps - A class action lawsuit has been filed, and investors who suffered losses in Sage have until October 28, 2024, to request to be appointed as lead plaintiff [4]. Cost Structure - The law firm represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Sage Therapeutics, Inc. for alleged misrepresentations regarding three of its drugs related to brain health during the specified class period from April 12, 2021, to July 23, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Sage Therapeutics made misrepresentations concerning zuranolone (SAGE-217/BIIB125), SAGE-718 (dalzanemdor), and SAGE-324 (BIIB124) [2]. - Investors who purchased or acquired Sage's securities during the class period are included in the lawsuit [1]. Group 2: Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file necessary documents by October 28, 2024 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4].

LOS ANGELES, Aug. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ: SAGE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), ...

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), have until October 28, 2024 to seek appointment as lead plaintiff of the Sage Therapeutics class action lawsuit. Captioned Korver v. Sage Therapeutics, Inc., No. 24-cv06511 (S.D.N.Y.), the Sage Therapeutics class action lawsuit charges Sage Therapeutics and certain of ...

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage Therapeutics" or "the Company") (NASDAQ: SAGE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (i) zuranolone was less effective in treating major depressive disorder ("MDD") than Defendants had led investo ...

Sage Therapeutics, Inc. (SAGE) reported a loss of $1.70 per share for the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.68. The company had reported a loss of $2.68 per share in the year-ago quarter. Revenues in the second quarter totaled $8.6 million, significantly up from $2.5 million reported in the year-ago period. The upside can be attributed to strong uptake for the recently launched depression drug Zurzuvae (zuranolone), which is marketed in partnership with drug gia ...